AXQ Capital’s Cabaletta Bio CABA Stock Holding History

AXQ Capital’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-28,938	Closed	-$77.8K	–	1025
2026 Q1	$77.8K	Buy	+28,938	New	+$80.4K	0.01%	898

Other funds holding CABA

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

AXQ Capital's CABA Position: Q2 2026 in Review

AXQ Capital sold out of Cabaletta Bio (CABA) in Q2 2026, closing a stake of 28,938 shares — an estimated $77.8K sold.

AXQ Capital first reported a position in CABA in Q1 2026 and held it in 1 quarter. The position peaked at $77.8K in Q1 2026. 140 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

AXQ Capital reported no remaining Cabaletta Bio position as of Q2 2026 after selling out during the quarter.
AXQ Capital sold 28,938 Cabaletta Bio shares in Q2 2026, an estimated $77.8K.
AXQ Capital first reported a position in Cabaletta Bio in Q1 2026 and held it in 1 quarter.
AXQ Capital's Cabaletta Bio position peaked at $77.8K in Q1 2026.
140 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on AXQ Capital's 13F filing for Q2 2026, filed 6 Aug 2026.